Protumoral roles of melanoma inhibitory activity 2 in oral squamous cell carcinoma

British Journal of Cancer

Volumn 108, Issue 7, 2013, Pages 1460-1469

  Kurihara, M ^a   Kirita, T ^a   Sasahira, T ^a   Ohmori, H ^a   Matsushima, S ^a   Yamamoto, K ^a   Bosserhoff, A K ^b   Kuniyasu, H ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; MELANOMA INHIBITORY ACTIVITY 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION;

AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRINS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MOUTH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84876489901     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.27     Document Type: Article

References (37)

1. Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, dos Santos-Pinto Jr D, Gutkind JS (2010) A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol 46(12): 880-887.
2. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8(6): 464-478. (Pubitemid 46823443)
3. Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8(8): 604-617.
4. Bauer R, Humphries M, Fassler R, Winklmeier A, Craig SE, Bosserhoff AK (2006) Regulation of integrin activity by MIA. J Biol Chem 281(17): 11669-11677. (Pubitemid 43855424)
5. Beck Jr L, D'Amore PA (1997) Vascular development: cellular and molecular regulation. FASEB J 11(5): 365-373. (Pubitemid 27193941)
6. Bosserhoff AK, Buettner R (2002) Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol 17(1): 289-300. (Pubitemid 34116431)
7. Bosserhoff AK, Moser M, Buettner R (2004) Characterization and expression pattern of the novel MIA homolog TANGO. Gene Expr Patterns 4(4): 473-479. (Pubitemid 38765073)
8. Bosserhoff AK, Moser M, Scholmerich J, Buettner R, Hellerbrand C (2003a) Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes. J Biol Chem 278(17): 15225-15231. (Pubitemid 36799858)
9. Bosserhoff AK, Stoll R, Sleeman JP, Bataille F, Buettner R, Holak TA (2003b) Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest 83(11): 1583-1594. (Pubitemid 37421099)
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917.
11. Fu BH, Wu ZZ, Qin J (2010) Effects of integrins on laminin chemotaxis by hepatocellular carcinoma cells. Mol Biol Rep 37(3): 1665-1670.
12. Hellerbrand C, Amann T, Schlegel J, Wild P, Bataille F, Spruss T, Hartmann A, Bosserhoff AK (2008) The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma. Gut 57(2): 243-251. (Pubitemid 351158054)
13. Hellerbrand C, Bataille F, Schlegel J, Hartmann A, Muhlbauer M, Scholmerich J, Buttner R, Hofstadter F, Bosserhoff AK (2005) In situ expression patterns of melanoma inhibitory activity 2 in healthy and diseased livers. Liver Int 25(2): 357-366.
14. Jachimczak P, Apfel R, Bosserhoff AK, Fabel K, Hau P, Tschertner I, Wise P, Schlingensiepen KH, Schuler-Thurner B, Bogdahn U (2005) Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int J Cancer 113(1): 88-92. (Pubitemid 39507314)
15. Kademani D, Bell RB, Bagheri S, Holmgren E, Dierks E, Potter B, Homer L (2005) Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg 63(11): 1599-1605. (Pubitemid 41525416)
16. Kreppel M, Eich HT, Kubler A, Zoller JE, Scheer M (2010) Prognostic value of the sixth edition of the UICC's TNM classification and stage grouping for oral cancer. J Surg Oncol 102(5): 443-449.
17. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196(2): 163-170. (Pubitemid 34110897)
18. Kuniyasu H, Sasaki T, Sasahira T, Ohmori H, Takahashi T (2004) Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 71(3): 129-136. (Pubitemid 38437707)
19. Kuniyasu H, Yasui W, Pettaway CA, Yano S, Oue N, Tahara E, Fidler IJ (2001) Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. Prostate 49(1): 19-29.
20. Lederman S, Cleary AM, Yellin MJ, Frank DM, Karpusas M, Thomas DW, Chess L (1996) The central role of the CD40-ligand and CD40 pathway in T-lymphocyte-mediated differentiation of B lymphocytes. Curr Opin Hematol 3(1): 77-86.
21. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4): 402-408. (Pubitemid 34164012)
22. Lopez-Graniel CM, Tamez de Leon D, Meneses-Garcia A, Gomez-Ruiz C, Frias-Mendivil M, Granados-Garcia M, Barrera-Franco JL (2001) Tumor angiogenesis as a prognostic factor in oral cavity carcinomas. J Exp Clin Cancer Res 20(4): 463-468. (Pubitemid 34087475)
23. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T (2012) Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 42(2): 139-147.
24. Miyahara M, Tanuma J, Sugihara K, Semba I (2007) Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer 110(6): 1287-1294. (Pubitemid 47435600)
25. Nagler RM (2002) Molecular aspects of oral cancer. Anticancer Res 22(5): 2977-2980. (Pubitemid 36069345)
26. O'Donnell RK, Kupferman M, Wei SJ, Singhal S (2005) Squamous cell carcinoma of the oral cavity with lymph node metastasis: NCBI Gene Expression Omnibus.
27. Poser I, Golob M, Buettner R, Bosserhoff AK (2003) Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23(8): 2991-2998. (Pubitemid 36403094)
28. Sasahira T, Kirita T, Kurihara M, Yamamoto K, Bhawal UK, Bosserhoff AK, Kuniyasu H (2010) MIA-dependent angiogenesis and lymphangiogenesis are closely associated with progression, nodal metastasis and poor prognosis in tongue squamous cell carcinoma. Eur J Cancer 46(12): 2285-2294.
29. Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, Fujii K, Ohmori H, Luo Y, Yasui W, Bosserhoff AK, Kuniyasu H (2008) High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 99(9): 1806-1812.
30. Savino W, Mendes-da-Cruz DA, Silva JS, Dardenne M, Cotta-de-Almeida V (2002) Intrathymic T-cell migration: a combinatorial interplay of extracellular matrix and chemokines? Trends Immunol 23(6): 305-313. (Pubitemid 34628774)
31. Shang ZJ, Li JR, Li ZB (2002) Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg 31(5): 495-498.
32. Shao J, Jung C, Liu C, Sheng H (2005) Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem 280(28): 26565-26572. (Pubitemid 41022254)
33. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H (2004) Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol 40(1): 13-20. (Pubitemid 37510207)
34. Su AI, Cooke MP, Ching KA, Hakak Y (2002) Large-scale analysis of the human transcriptome (HG-U95A): NCBI Gene Expression Omnibus.
35. Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K, Koji T (1999) Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 80(1-2): 309-313. (Pubitemid 29210123)
36. Xu Y, Yang Y, Cai Y, Liu F, Liu Y, Zhu Y, Wu J (2011) The X protein of hepatitis B virus activates hepatoma cell proliferation through repressing melanoma inhibitory activity 2 gene. Biochem Biophys Res Commun 416(3-4): 379-384.
37. Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, Taniguchi K, Miwa K, Ohoyama S, Sugiyama K, Sasaki T (1999) Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 5(7): 1823-1829. (Pubitemid 29334464)